Shares of Repare Therapeutics Inc. (RPTX.O) experienced a notable increase today, crossing above its 5-day simple moving average (SMA), reflecting a positive shift in investor sentiment. This uptick comes amid an ongoing investigation by Halper Sadeh LLC into the fairness of Repare's sale to XenoTherapeutics, which has raised questions about the adequacy of the $1.82 per share compensation offered to shareholders. The investigation highlights potential breaches of fiduciary duty by Repare's board, particularly regarding the lack of competitive bidding and essential disclosures related to the merger. Despite these concerns, Repare's recent earnings performance, which exceeded expectations with break-even quarterly earnings and significant revenue growth, has contributed to a bullish outlook, with shares up approximately 29% year-to-date.
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
Current: 2.650
Low
3.00
Averages
3.00
High
3.00
TD Cowen
Marc Frahm
Buy
to
Hold
downgrade
$1.82
2025-11-17
Reason
TD Cowen
Marc Frahm
Price Target
$1.82
AI Analysis
2025-11-17
downgrade
Buy
to
Hold
Reason
TD Cowen analyst Marc Frahm downgraded Repare Therapeutics to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
H.C. Wainwright
Buy
downgrade
$5 -> $3
2025-10-27
Reason
H.C. Wainwright
Price Target
$5 -> $3
2025-10-27
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Repare Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data "raises questions over its viability." As such, the firm removed risk-adjusted revenue forecasts for the agent.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPTX
Unlock Now
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$10 → $5
2025-03-07
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$10 → $5
2025-03-07
Maintains
Strong Buy
Reason
About RPTX
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
